Elevated Heart‐Type Fatty Acid‐Binding Protein Predicts Early Myocardial Injury and Aids in the Diagnosis of Non‐St Elevation Myocardial Infarction

Naroo, GY; Ali, Samir; Butros, V; Mohammed, Ishaq; Alosert, M; Terris, James; Fikree, Moin

doi:10.1177/102490790901600303

Cited by 11 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Dua ragaman lain dari ACS, NSTEMI dan APTS dibedakan oleh keberadaan petanda biologis jantung positif. 5,15 Heart Fatty Acid Binding Protein (H-FABP) sebagai penunjuk dini untuk penilaian kerusakan otot jantung di pasien dengan nyeri dada jantung yang khas dan EKG nonkonklusif. Heart-FABP adalah protein sitoplasma dengan berat molekul rendah (15 kDa) yang terdapat dalam kepekatan tinggi dalam jaringan otot jantung.…”

Section: -175unclassified

See 1 more Smart Citation

Heart Fatty Acid Binding Protein Sebagai Petanda Biologis Diagnosis Sindrom Koroner Akut

Puspitawati¹,

Sudana²,

Setyawati³

et al. 2018

Indonesian J. Clin. Pathol. Med. Lab.

View full text Add to dashboard Cite

Heart-Fatty Acid-Binding Protein (H-FABP) is a membrane-bound protein that facilitates transport of fatty acids from the blood intothe heart. It is a low molecular weight cytoplasmic protein. Because of its small size and location, it is released rapidly into the bloodfollowing myocardial damage. The H-FABP levels rise as early as between 1−3 hours after the onset of Acute Coronary Syndrome, thepeak situation between 6−-8 hours, and returns to normal within 24 hours. The purpose of this study was to know the cut-off value ofHeart Fatty Acid Binding Protein with a sensitivity of at least 90% in patients with acute coronary syndrome in the Dr. Sardjito HospitalYogyakarta. The researchers undertook a cross sectional evaluation of 75 consecutive patients admitted with acute chest pain suggestiveof acute coronary syndrome (ACS). The H-FABP was measured by using immunoturbidimetry assay methods. The receiver operatingcharacteristic (ROC) analysis was calculated for the cut off point, sensitivity and specificity estimation. A total of 75 patients (59 in theACS group and 16 in the control group) were included in this study, and the majority of the ACS group (64 [76.2%]) were male patientswith AMI, 20 (26.7%) had an ST-elevation myocardial infarction and the rest (21 [28%]) had a non–ST-elevation myocardial infarction.The optimized cut-off obtained for h-FABP was 15 ng/mL, showing a sensitivity and specificity of the H-FABP assay for detecting ACSas 98.31 (95% CI 90 to 100) and 93.75% (95% CI 86 to 99), respectively. The areas under the receiver operator characteristic (ROC)curves to distinguish ACS from non-ACS were 0.983 (95% CI: 0.927– 0.999) for H-FABP. The optimized cut-off obtained for H-FABPwas 15 ng/mL, showing a 98.31% sensitivity and 93.75% specificity for detecting ACS in the Dr. Sardjito Hospital Yogyakarta.

show abstract

Section: -175unclassified

“…Dengan demikian biaya setelah komplikasi infark miokard yang cukup besar untuk perawatan kesehatan dapat dihemat. 14,15 Keterbatasan penelitian ini adalah rancangan kajian potong lintang yang tidak dapat melihat perubahan/ peningkatan tingkat H-FABP sesuai spektrum pada manifestasi klinis SKA menurut waktu.…”

Section: -175unclassified

Heart Fatty Acid Binding Protein Sebagai Petanda Biologis Diagnosis Sindrom Koroner Akut

Puspitawati¹,

Sudana²,

Setyawati³

et al. 2018

Indonesian J. Clin. Pathol. Med. Lab.

View full text Add to dashboard Cite

show abstract

“…Óðîâåíü FABP â ñûâîðîòêå êðîâè íå ìåíÿåòñÿ ñ âîçðàñòîì è íå çàâèñèò îò âðåìåíè ñóòîê. Êèíåòèêà ïîâûøåíèÿ óðîâíÿ h-FABP â êðîâè ïîçâîëÿåò äåòåêòèðîâàòü óâå-ëè÷åíèå åãî êîíöåíòðàöèè óaeå ÷åðåç 30 ìèíóò ïîñëå ïîÿâëåíèÿ àíãèíîçíûõ áîëåé, äîñòèãàÿ ìàêñèìóìà ÷åðåç 6-8 ÷àñîâ, â òå÷åíèå 12-24 ÷àñîâ óðîâåíü h-FABP ñíèaeàåòñÿ äî íîðìàëüíûõ çíà÷åíèé [31]. Ïî äàííûì èññëåäîâàíèé, ïðîâåäåííûõ â ïîñëåäíåå âðåìÿ, óñòàíîâëåíî, ÷òî h-FABP â ïåðâûå 3-6 ÷àñîâ ïîñëå íà÷àëà àíãèíîçíîãî ïðèñòóïà ïî ÷óâñòâèòåëüíîñòè è ñïåöèôè÷íîñòè ïðåâîñõîäèò òðîïîíèíû, ìèîãëîáèí, è êðåàòèíêèíàçó.…”

Section: ñîâðåìåííîå âîççðåíèå íà ïðåäèêöèþ èøåìèè ìèîêàðäà áèîìàðêåðàìèunclassified

Markers of myocardial ischemia: pathophysiological substantiation of clinical application

Лямина¹,

Карпова²,

Котельникова³

2018

Nauchno-Prakticheskii Zhurnal «Patogenez»

View full text Add to dashboard Cite

Распространенность сердечно-сосудистых заболеваний с проявлениями ишемии диктует необходимость поиска методов, которые позволяют выявлять ишемию на ранних этапах ее развития, что дает возможность более эффективного лечения, корректирования состояния больных и предупреждения возможных осложнений. В современной клинической практике для диагностики ишемической болезни сердца применяется множество методов различных по своей достоверности и информативности. Одним из перспективных методов ранней диагностики ишемической болезни сердца является идентификация биохимических и молекулярных маркеров, которые чувствительны и специфичны для ишемического повреждения миокарда на ранних сроках в отсутствии некроза и повышения маркеров клеточного повреждения кардиомиоцитов. Использование биомаркеров ранней диагностики ишемии является перспективным подходом к решению комплексной задачи безопасного кардиомониторинга больных с различными сердечно-сосудистыми заболеваниями. Благодаря определению достаточно простых, но вместе с этим высокочувствительных и специфичных маркеров ишемии миокарда и кардиопротекции можно значительно повысить эффективность оказания медицинской помощи. Prevalence of cardiovascular diseases with manifestations of ischemia dictates requirement for methods for early detection of ischemia, which provides more effective treatment, correction of patient’s condition, and prevention of possible complications. In modern clinical practice, a variety of methods is used for detection of IHD, which differ in their reliability and informativeness. One of promising methods for early diagnosis of coronary heart disease is identification of biochemical and molecular markers that are sensitive and specific for early ischemic damage of the myocardium in the absence of necrosis and increased markers of cardiomyocyte injury. The use of biomarkers for early diagnosis of ischemia is a promising approach to solving the complex problem of safe cardiomonitoring in patients with different cardiovascular diseases. By identifying rather simple but at the same time highly sensitive and specific markers for myocardial ischemia and cardioprotection, the efficiency of medical care can be significantly improved.

show abstract

“…Eerdere onderzoeken met de Cardiodetect® hadden een vergelijkbaar resultaat, met positief en negatief voorspellende waarden van 63-100% respectievelijk 47-97%. [11][12][13][14][15][16] Deze onderzoeken zijn echter niet rechtstreeks te vergelijken, vanwege verschillen in de samenstelling van de deelnemersgroep, de ernst van het ACS en de priorkans op ACS (13 tot 64%). 17 Ons onderzoek laat zien dat de H-FABP-sneltest toegevoegde waarde heeft bovenop de anamnese, maar omdat huisartsen liefst niemand met een ACS willen missen is 15% foutnegatieve uitslagen te hoog.…”

Section: Discussieunclassified

De H-FABP-sneltest bij verdenking op acuut coronair syndroom

Slot

Rutten

Heijden

et al. 2014

HUISARTS WETENSCHAP

View full text Add to dashboard Cite

People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.• The final author version and the galley proof are versions of the publication after peer review.• The final published version features the final layout of the paper including the volume, issue and page numbers. Link to publication General rightsCopyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal.If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

show abstract

Elevated Heart‐Type Fatty Acid‐Binding Protein Predicts Early Myocardial Injury and Aids in the Diagnosis of Non‐St Elevation Myocardial Infarction

Cited by 11 publications

References 17 publications

Heart Fatty Acid Binding Protein Sebagai Petanda Biologis Diagnosis Sindrom Koroner Akut

Heart Fatty Acid Binding Protein Sebagai Petanda Biologis Diagnosis Sindrom Koroner Akut

Markers of myocardial ischemia: pathophysiological substantiation of clinical application

De H-FABP-sneltest bij verdenking op acuut coronair syndroom

Contact Info

Product

Resources

About